A 12-month, Multicenter, Open Label, Randomized, Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced CNI, and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients With a 24-month Additional Safety Follow-up
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms CRADLE
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 14 May 2020 Results assessing three-year outcomes from this study, published in the American Journal of Transplantation.
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.
- 20 Aug 2018 Results published in the American Journal of Transplantation.